Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus LISINOPRIL AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus LISINOPRIL AND HYDROCHLOROTHIAZIDE.
ACEON vs LISINOPRIL AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Lisinopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
Initial dose: 10 mg/12.5 mg orally once daily. Titrate based on blood pressure response; maximum 40 mg/25 mg per day.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Lisinopril: terminal half-life 12 hours, effective half-life ~30 hours due to prolonged ACE inhibition. Hydrochlorothiazide: terminal half-life 5.6-14.8 hours (mean 9.6 hours) in patients with normal renal function.
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Lisinopril: primarily renal (100% unchanged in urine). Hydrochlorothiazide: renal (≥95% unchanged via tubular secretion).
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor